Lamassu Pharma

Lamassu Pharma is a biotech startup that solves the critical unmet medical need for severe acute pancreatitis. Their lead candidate is a novel small molecule therapy for acute pancreatitis. This was developed at Mayo Clinic by leading scientists and has profound preclinical efficacy to completely mitigate mortality and morbidity associated with severe acute pancreatitis. We are currently focused on the continued development of this compound through safety testing in preparation for definitive clinical trials. Our ultimate goal is to save the lives of patients afflicted with this disease.